Therapeutic immunoglobulins are used in the treatment of immunodeficiencies as well as several autoimmune and inflammatory diseases. These intravenous immunoglobulins (IVIg) represent the healthy human IgG repertoire,...Therapeutic immunoglobulins are used in the treatment of immunodeficiencies as well as several autoimmune and inflammatory diseases. These intravenous immunoglobulins (IVIg) represent the healthy human IgG repertoire, which can be reactive for both self and non-self antigens. A better characterization of IVIg’s repertoire is an important aspect to enable its effective utilization as an immunomodulatory treatment. In this study we have investigated the reactivity of IgG1, IgG2, IgG3 and IgG4 present in IVIg for a small selection of antigens, including actin, DNA, ferritin and thyroglobulin. We observed that two commercial preparations of therapeutic immunoglobulins contain very high reactivity for thyroglobulin, which was predominantly detected by IgG4. Since IgG4 antibodies can have immunomodulatory properties, these result suggest that these anti-thyroglobulin may have a role in the IVIg treatment of autoimmune disease characterized by high avidity for anti-thyroglobulin antibodies such as Hashimoto’s disease.展开更多
目的总结静脉输注人免疫球蛋白（Human immunoglobulin for intravenous injections,IGIV）不良反应的临床特点,为临床合理应用IGIV提供参考。方法回顾性分析2015年6月我科发生的1例IGIV不良反应患者,并对已有文献报道进行综述,总结IGI...目的总结静脉输注人免疫球蛋白（Human immunoglobulin for intravenous injections,IGIV）不良反应的临床特点,为临床合理应用IGIV提供参考。方法回顾性分析2015年6月我科发生的1例IGIV不良反应患者,并对已有文献报道进行综述,总结IGIV不良反应的临床特点。结果根据文献综述,结合本病例分析发现,有20%~50%的IGIV患者5%~15%例次,在输液过程出现不良反应。IGIV不良反应包括局部不良反应和全身不良反应。局部不良反应表现为：持续性疼痛、青紫、肿胀、红斑等,很少见;全身不良反应表现为：全身酸痛、畏寒、发热等,较常见,且病情较轻。全身不良反应还包括一些罕见且严重的反应,包括肺部疾病、肠炎、皮肤科疾病、传染病和动静脉血栓形成。结论 IGIV不良反应较常见,表现形式多种多样,及时识别是治疗关键。展开更多
文摘Therapeutic immunoglobulins are used in the treatment of immunodeficiencies as well as several autoimmune and inflammatory diseases. These intravenous immunoglobulins (IVIg) represent the healthy human IgG repertoire, which can be reactive for both self and non-self antigens. A better characterization of IVIg’s repertoire is an important aspect to enable its effective utilization as an immunomodulatory treatment. In this study we have investigated the reactivity of IgG1, IgG2, IgG3 and IgG4 present in IVIg for a small selection of antigens, including actin, DNA, ferritin and thyroglobulin. We observed that two commercial preparations of therapeutic immunoglobulins contain very high reactivity for thyroglobulin, which was predominantly detected by IgG4. Since IgG4 antibodies can have immunomodulatory properties, these result suggest that these anti-thyroglobulin may have a role in the IVIg treatment of autoimmune disease characterized by high avidity for anti-thyroglobulin antibodies such as Hashimoto’s disease.
